Sec Form 13D Filing - SMITH CLARENCE EDWARD filing for ProtoKinetix, Incorporated (PKTX) - 2021-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 16)*

PROTOKINETIX, INCORPORATED

(Name of Issuer)

Common Stock, par value $0.0000053 per share

(Title of Class of Securities)

743722100

(CUSIP Number)

Clarence E. Smith
1845 County Road #214
St. Augustine, Florida 32084
(304) 299-5070 

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 4, 2021

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 ___________________________

 ¹ Includes 29,161,110 shares of common stock held by Mr. Smith personally; 13,235,160 shares held in Mr. Smith’s trust; 1,850,000 held in Mr. Smith’s retirement account; 26,250,000 shares owned directly by Mr. Smith by virtue of holding options exercisable in accordance with Rule 13d-1; and 359,523 shares owed directly by Mr. Smith by virtue of holding warrants exercisable in accordance with Rule 13d-1.

This Amendment No. 16 to Schedule 13D, dated August 6, 2021 (this “Amendment No. 16”), is being filed by the undersigned to amend the Schedule 13D originally filed on March 24, 2014 (the “Original 13D”), Amendment No. 1 to the Original 13D filed on July 8, 2015, Amendment No. 2 filed on May 5, 2016, Amendment No. 3 filed on July 11, 2016, Amendment No. 4 filed on September 19, 2016, Amendment No. 5 filed on November 7, 2016, Amendment No. 6 filed on December 7, 2016, Amendment No. 7 filed on December 22, 2016, Amendment No. 8 filed on December 23, 2016, Amendment No. 9 filed on January 17, 2018, Amendment No. 10 filed on June 12, 2018, Amendment No. 11 filed on January 17, 2019, Amendment No. 12 filed on April 16, 2019, Amendment No. 13 filed on July 17, 2019, Amendment No. 14 filed on April 1, 2020, and Amendment No. 15 filed on August 7, 2020. This Amendment No. 16 relates to the common stock, $0.0000053 par value, of ProtoKinetix, Incorporated (“ProtoKinetix” or the “Company”). This Amendment No. 16 is being filed by Mr. Smith to report an increase in his beneficial ownership of common stock due to the acquisition of additional common stock, warrants to purchase common stock, and stock options of ProtoKinetix in private placements. Except as set forth herein, the Original Schedule 13D is unmodified.

ITEM 1. SECURITY AND ISSUER

The principal executive offices of ProtoKinetix are presently located at 412 Mulberry Street, Marietta, Ohio 45750.

ITEM 2. IDENTITY AND BACKGROUND

(c) Oil and gas industry entrepreneur. Mr. Smith’s primary occupation is President, Chief Executive Officer and Director of ProtoKinetix. ProtoKinetix’s principal address is 412 Mulberry Street, Marietta, Ohio 45750.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

On November 2, 2020, Mr. Smith acquired 107,143 shares of common stock of ProtoKinetix pursuant to a private placement.

On January 12, 2021, Mr. Smith acquired 142,857 shares of common stock at a price of $0.07 per share, and warrants to purchase 142,857 shares of common stock at a price of $0.07 per shares pursuant to a private placement.

On August 4, 2021, Mr. Smith was granted 2,600,000 stock options with an exercise price of $0.11 pursuant to the Protokinetix 2017 Amended Stock Option and Stock Bonus Plan, with 1,250,000 options vested.

ITEM 4. PURPOSE OF THE TRANSACTION

No change.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a)               Mr. Smith beneficially owns 70,855,793 shares of common stock of ProtoKinetix which amounts to approximately 22.15% of the total number of common shares currently outstanding, of which 29,161,110 are owned directly by Mr. Smith, or held in a brokerage account for his benefit, 13,235,160 shares are owned indirectly by Mr. Smith through his trusts, 1,850,000 are owned indirectly by Mr. Smith through his retirement account, 26,250,000 shares are owned directly by Mr. Smith by virtue of holding options exercisable in accordance with Rule 13d-1, and 359,523 shares are owned directly by Mr. Smith by virtue of holding warrants exercisable in accordance with Rule 13d-1.

(b)               Mr. Smith has sole voting and dispositive power over 70,855,793 shares of common stock of ProtoKinetix.

(c)                Please see Item 3 above for a description of securities transactions.

(d)               No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock described herein, except as described in Item 6, below.

(e)                Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE SECURITIES OF THE ISSUER.

No change.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

No change.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.